Roche to market Good Start Genetics’ carrier screening tech

The partnership between Roche and Good Start Genetics will increase testing options for parents seeking to gauge the risk of genetic conditions in their children.

Good Start Genetics, whose genetic carrier screening platform is offered at fertility centers, announced it is tapping Roche to market the technology to obstetricians and general practitioners in the U.S.

Roche will market the GeneVu platform alongside its own Harmony noninvasive prenatal test, according to a statement. While Harmony specifically detects Down syndrome, Edward syndrome and Patau syndrome, GeneVu offers an extensive number of additional tests that patients and physicians may choose from, including ethnicity-specific tests for blood disorders.

"Offering GeneVu, our comprehensive and highly accurate carrier screening test service for inherited genetic disorders, with Roche's Harmony NIPT service, which assesses the risk of fetal trisomy 21, 18, 13, and sex chromosome aneuploidy, provides the 20,000+ OBGYNs in the United States with two best-in-class solutions for their expectant moms,” said Good Start Genetics CEO Jeffrey Luber in a statement.


Webinar: The Key to Continuous Compliance for Medical Device Software Developers

Risk is not an option in medical device software development. You need to mitigate time-to-market, FDA, and security risks, or you could be facing a costly recall or software update. Attend this webinar to learn how to use static analysis to ensure continuous compliance with industry standards and regulatory requirements, improve security for increasingly connected medical devices, and enforce corporate and industry coding rules and best practices.

GeneVu uses next-generation sequencing to detect mutations and carriers during prenatal testing. It is approved in the U.S. as a lab-developed test and is not FDA-approved for commercial distribution.

Last month, Good Start launched a low-cost, NGS test on Amazon. VeriYou, initially introduced in October, is available for $149 and tests for cystic fibrosis and spinal muscular atrophy. The partnership, the online retailer’s first with a genetic testing company, aims to widen access to carrier screening for these two disorders.

Suggested Articles

Cornell researchers found that inhibiting a long noncoding RNA called SAF caused HIV-infected cells to self-destruct.

Liquid biopsy developer Epic Sciences has brought on Myriad Genetics’ oncology chief, Lloyd Sanders, to be its new president and CEO.

Thermo Fisher Scientific has moved to acquire viral vector developer and manufacturer Brammer Bio for $1.7 billion in cash.